{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Carcinomas+%28NEC%29", "query": { "condition": "Neuroendocrine Carcinomas (NEC)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 17, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Carcinomas+%28NEC%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T07:49:28.576Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07174583", "title": "A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small-cell Lung Cancer", "Neuroendocrine Carcinomas", "Solid Tumor Show to Express DLL3" ], "interventions": [ { "name": "IDE849", "type": "DRUG" }, { "name": "durvalumab", "type": "DRUG" }, { "name": "IDE161", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IDEAYA Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 208, "start_date": "2025-10-14", "completion_date": "2029-05", "has_results": false, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-05-22T07:49:28.576Z", "location_count": 20, "location_summary": "Denver, Colorado • Jacksonville, Florida • Orlando, Florida + 14 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07174583" }, { "nct_id": "NCT06132113", "title": "DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroendocrine Neoplasms" ], "interventions": [ { "name": "BI 764532", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2024-01-22", "completion_date": "2027-04-25", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-05-22T07:49:28.576Z", "location_count": 5, "location_summary": "Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 2 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06132113" }, { "nct_id": "NCT02955069", "title": "Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Well-differentiated Non-functional NET of Thoracic Origin", "Well-differentiated Non-functional NET of Gastrointestinal Origin", "Well-differentiated Non-functional NET of Pancreatic Origin", "Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma" ], "interventions": [ { "name": "PDR001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 116, "start_date": "2017-02-14", "completion_date": "2020-05-13", "has_results": true, "last_update_posted_date": "2021-04-12", "last_synced_at": "2026-05-22T07:49:28.576Z", "location_count": 7, "location_summary": "Duarte, California • Denver, Colorado • Tampa, Florida + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02955069" }, { "nct_id": "NCT07006727", "title": "Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Small Cell Lung Carcinoma", "Large Cell Neuroendocrine Carcinoma of the Lung", "Neuroendocrine Prostate Cancer", "Gastroenteropancreatic Neuroendocrine Carcinoma" ], "interventions": [ { "name": "225Ac-ETN029", "type": "DRUG" }, { "name": "111In-ETN029", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 116, "start_date": "2025-10-16", "completion_date": "2031-08-29", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-05-22T07:49:28.576Z", "location_count": 4, "location_summary": "Iowa City, Iowa • Boston, Massachusetts • Royal Oak, Michigan + 1 more", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Royal Oak", "state": "Michigan" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07006727" }, { "nct_id": "NCT06943521", "title": "A Study of MT-4561 in Patients With Various Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Non-small Cell Lung Cancer (NSCLC)", "Esophageal Cancer", "Gastric Cancer", "Biliary Tract Cancer", "Pancreatic Ductal Adenocarcinoma (PDAC)", "Breast Cancer", "Ovarian Cancer", "Cervical Cancer", "Endometrial Cancer", "Prostate Cancer", "Urothelial Carcinoma", "Neuroendocrine Tumor (NET)", "Neuroendocrine Carcinoma (NEC)", "Soft Tissue Sarcoma", "Nuclear Protein in Testis (NUT) Carcinoma" ], "interventions": [ { "name": "MT-4561", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tanabe Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2025-04-18", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-05-22T07:49:28.576Z", "location_count": 4, "location_summary": "Los Angeles, California • Grand Rapids, Michigan • Columbus, Ohio + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06943521" }, { "nct_id": "NCT03136055", "title": "Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2017-06-20", "completion_date": "2021-10-31", "has_results": true, "last_update_posted_date": "2022-12-27", "last_synced_at": "2026-05-22T07:49:28.576Z", "location_count": 3, "location_summary": "San Francisco, California • Boston, Massachusetts • New York, New York", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03136055" }, { "nct_id": "NCT04701307", "title": "Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Small Cell Carcinoma", "Neuroendocrine Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8" ], "interventions": [ { "name": "Dostarlimab", "type": "BIOLOGICAL" }, { "name": "Niraparib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2021-02-01", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-05-22T07:49:28.576Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04701307" }, { "nct_id": "NCT05652686", "title": "A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Cell Lung Cancer (SCLC)", "Large Cell Neuroendocrine Cancer (LCNEC)", "Neuroendocrine Prostate Cancer (NEPC)", "Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)", "Neuroendocrine Carcinomas (NEC)", "Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)" ], "interventions": [ { "name": "Peluntamig (PT217)", "type": "DRUG" }, { "name": "Carboplatin + Etoposide", "type": "DRUG" }, { "name": "Paclitaxel.", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Phanes Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 203, "start_date": "2023-09-05", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2025-09-23", "last_synced_at": "2026-05-22T07:49:28.576Z", "location_count": 12, "location_summary": "Duarte, California • Denver, Colorado • Baltimore, Maryland + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05652686" }, { "nct_id": "NCT07488923", "title": "A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Small Cell Lung Cancer (SCLC )", "Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)", "Gastroenteropancreatic NEC (GEP NEC)", "Neuroendocrine Prostate Cancer (NEPC)" ], "interventions": [ { "name": "ML261", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Moonlight Bio, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2026-05", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-05-22T07:49:28.576Z", "location_count": 3, "location_summary": "Hackensack, New Jersey • New York, New York • Nashville, Tennessee", "locations": [ { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07488923" }, { "nct_id": "NCT06406465", "title": "A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Neuroendocrine", "Tumor, Neuroendocrine", "Tumors, Neuroendocrine", "Neuroendocrine; Carcinoma", "Small Cell; Receptors" ], "interventions": [ { "name": "Belinostat", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 60, "start_date": "2026-05-25", "completion_date": "2028-07-30", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-05-22T07:49:28.576Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06406465" } ] }